euro adhoc: Sartorius AG / Financial Figures/Balance Sheet / Currency-adjusted sales revenue up 2.8%; order intake in constant currencies up 0.9%; operating result (EBITA) at EUR40.6 million; EBITA ma

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Figures for the First Nine Months of 2008

28.10.2008

To ensure the best possible comparability, the figures of the
year-earlier period are presented on a pro forma basis and adjusted
for non-operating effects.

For the nine-month period, the Sartorius Group achieved a
currency-adjusted gain of 2.8%. Consolidated sales revenue in the
reporting currency is at EUR453.4 million (2007 pro forma: EUR458.8
mn; -1.2%). The Biotechnology Division's sales revenue was up a
currency-adjusted 1.0%, but edged down 3.0% in the reporting
currency, from EUR281.8 mn to EUR273.3 mn. The Mechatronics
Division´s revenue grew 1.7% (currency-adjusted: +5.5%) from EUR177.0
mn to EUR180.0 mn. The Group´s order intake eased 3.0%
(currency-adjusted: +0.9%) from EUR468.2 mn to EUR454.0 mn
(Biotechnology: -5.1%, currency-adjusted: -1.1%; Mechatronics: +0.2%,
currency-adjusted: +3.9%.

Operating earnings (EBITA) are at EUR40.6 million relative to EUR46.9
million a year ago (Biotechnology: EUR29.1 mn vs. EUR35.2 mn in 2007;
Mechatronics: EUR11.4 mn vs. EUR11.7 mn in 2007). Currency effects
and the higher R&D costs budgeted weighed down on earnings.
Particularly impacted by the higher euro-zone base interest rate,
consolidated net profit after minority interest totals EUR10.0 mn
(2007: EUR16.2 mn). Earnings per share, excluding the two non-cash
items of amortization and interest for the share price warrants
granted, are accordingly at EUR0.80 (2007: EUR1.11).

In view of the increasingly difficult global economic conditions, we
currently do not consider it possible to make an accurate and
reliable quantitative forecast of further business development. We
continue to see ourselves well-positioned in our markets, but do not
expect to reach the full-year targets we announced on the basis of
our first-half 2008 figures, because of the gloomy economic
environment. However, we do anticipate a robust operating result for
the fourth quarter as well.

in millions of EUR (unless 9-month 2008 9-month 2007 Change
otherwise specified) pro forma in %

Sartorius Group
Sales revenue 453.4 458.8 -1.2 (+2.8)
Order intake 454.0 468.2 -3.0 (+0.9)
EBITA 1) 40.6 46.9 -13.6
Net profit 1)2) 13.7 18.9 -27.8
Earnings per share 1)2) in EUR 0.80 1.11

Biotechnology Division
Sales revenue 273.3 281.8 -3.0 (+1.0)
Order intake 269.3 283.8 -5.1 (-1.1)
EBITA 1) 29.1 35.2 -17.2

Mechatronics Division
Sales revenue 180.0 177.0 +1.7 (+5.5)
Order intake 184.8 184.5 +0.2 (+3.9)
EBITA 1) 11.4 11.7 -2.8

in parentheses: currency-adjusted 1) For 2007 adjusted for
non-operating effects 2) Excluding non-cash amortization and, for
2008, additionally excluding non-cash interest expenses for share
price warrants

Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the nine-month
results for Sartorius with analysts and investors in a teleconference
today (Oct. 28, 2008) at 3 p.m. CET. You may dial into this
teleconference starting at 2:45 p.m. CET at the following numbers:

Germany: +49 (0) 69 2222 2220; France: +33 (0) 1 70 99 42 82;
UK: +44 (0) 20 7138 0839; USA: +1 718 354 1362

The dial-in code is: 4944170.

To view the webcast, log onto http://www.sartorius.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Andreas Wiederhold

Treasury & Investor Relations

Telefon: +49 (0)551 308-1668

E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade